NEW YORK (GenomeWeb) – Metabolon today announced a collaboration to provide metabolomic profiling services to GlaxoSmithKline.
The two firms also will collaborate on research projects using Metabolon's DiscoveryHD4 platform. Financial and other terms of the agreement were not disclosed.
GSK will have access to Metabolon's bioinformatics tools, proprietary disease ontologies, and visualization tools to integrate metabolomics data with existing genomics and proteomics data, Metabolon said.
"We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic 'picture' with the aim of yielding translatable, meaningful results," Metabolon President and CEO John Ryals said in a statement. "Gaps of knowledge can be bridged through the understanding [that] metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost."